Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole

de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Attard, 2008, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven, J Clin Oncol, 26, 4563, 10.1200/JCO.2007.15.9749 Ryan, 2010, Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy, J Clin Oncol, 28, 1481, 10.1200/JCO.2009.24.1281 Reid, 2008, CYP17 inhibition as a hormonal strategy for prostate cancer, Nat Clin Pract Urol, 5, 610, 10.1038/ncpuro1237 Keizman, 2012, Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression, Prostate, 72, 461, 10.1002/pros.21447 Danila, 2010, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer, J Clin Oncol, 28, 1496, 10.1200/JCO.2009.25.9259 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Leibowitz-Amit, 2014, Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer., Ann Oncol, 5, 657, 10.1093/annonc/mdt581 Chi, 2013, A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel, ASCO Meeting Abst, 31, 5013 Booth, 2013, Evaluation of treatment benefit: randomized controlled trials and population-based observational research, J Clin Oncol, 31, 3298, 10.1200/JCO.2013.51.5023 Chi, 2013, Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), Eur J Cancer Hart, 2014, An incidence model of the cost of advanced prostate cancer in Spain, J Med Econ, 17, 125, 10.3111/13696998.2013.877020 Mailankody, 2014, Comparative effectiveness questions in oncology, N Engl J Med, 370, 1478, 10.1056/NEJMp1400104 Yap, 2008, Targeting CYP17: established and novel approaches in prostate cancer, Curr Opin Pharmacol, 8, 449, 10.1016/j.coph.2008.06.004 Chan, 1996, 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer, J Med Chem, 39, 3319, 10.1021/jm950749y Small, 2004, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583), J Clin Oncol, 22, 1025, 10.1200/JCO.2004.06.037 Halabi, 2003, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 21, 1232, 10.1200/JCO.2003.06.100